Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505907 | 1.00 | TSHR (0.56) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL937356 | 1.00 | TSHR (0.56) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL46155 | 0.86 | TSHR (0.72) | TSHR | |
| SCHEMBL16422345 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21353917 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21363715 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21353919 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL21393372 | 0.81 | KDM1A (0.39) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL16423075 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C | |
| SCHEMBL16422344 | 0.81 | KDM1A (0.48) | TSHRKDM1ASLC6A2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119662578-A | Styrene monooxygenase combined mutant and application thereof | 中国科学院成都生物研究所 | 2025-03-21 | — | — | CN | claimed |
| CN-115927276-B | Halohydrin dehalogenase mutant and application thereof in synthesis of chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2024-08-27 | — | — | CN | claimed |
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| CN-119662578-A | Styrene monooxygenase combined mutant and application thereof | 中国科学院成都生物研究所 | 2025-03-21 | — | — | CN | disclosed |
| CN-115927276-B | Halohydrin dehalogenase mutant and application thereof in synthesis of chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2024-08-27 | — | — | CN | disclosed |
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-115927276-A | Halogen alcohol dehalogenase mutant and application thereof in synthesizing chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2023-04-07 | — | — | CN | disclosed |
| CN-113106139-B | Method for preparing chiral organic compound by catalyzing styrene and derivatives thereof | 中国科学院青岛生物能源与过程研究所 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2009005646-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
| US-7153971-B2 | Contacting a carbohydrate with an amine to produce amino tetrahydroxy carbohydrate, protecting two hydroxy groups of tetrahydroxy carbohydrate, forming hydroxy heterocyclic-spiro moiety by reacting with activated carbonate, oxidizing OH | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | disclosed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | TSHR 623/4885KDM1A 2399/4885SLC6A2 2/4885 |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | OXER1, OXA1L, AOX1 | TSHR 4087/4885KDM1A 1928/4885SLC6A2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.